Long-Term Triplet Therapy Extends Survival in Metastatic Prostate Cancer

Long-term results from the Phase 3 PEACE-1 trial, presented at the ESMO Congress 2026, indicate that adding abiraterone to initial treatment significantly reduces the risk of death by 25% in men with metastatic prostate cancer, with the benefit strengthening over time. For those receiving ADT plus docetaxel, adding abiraterone further reduced the risk of death by 32%, increasing median survival from 4.4 to 6.2 years.